50/50 (2011) and Soft-Tissue Sarcoma of the Spine

This page is for viewers of the 2011 film 50/50 who want to know how its cancer story compares with real soft tissue sarcoma. It covers the plot, the symptoms, how common the cancer is, and how it is treated.

Adam Lerner is 27 and writes for public radio in Seattle. He has back pain that will not settle. A scan finds a tumor lying along his spine. The word he is handed is neurofibrosarcoma, a sarcoma of the sheath around a nerve. His doctor dictates the diagnosis into a recorder while Adam sits in front of him. Chemotherapy follows, then surgery. His girlfriend leaves. His friend Kyle is crude, unreliable, and the only person who keeps treating him normally. His therapist is 24 and still in training. Will Reiser wrote the screenplay after his own diagnosis.

Spoilers throughout. Talking about the cancer storyline means talking about how it ends.

How Adam's cancer is found is worth noticing. He had back pain that did not go away. His back pain did not go away and had no obvious cause. Pain that lasts is worth a visit to a clinician.

NCI describes a soft tissue sarcoma differently. It may appear as a painless lump under the skin, often on an arm or a leg. Sarcomas that begin in the abdomen may cause nothing at all until they are very large. Pain and trouble breathing come later, when the tumor presses on nearby nerves, muscles, organs or blood vessels.

So the film's version, with pain and no lump, is not the picture NCI leads with. NCI says pain can come as a tumor grows and presses on nearby nerves, muscles, organs or blood vessels.

Numbers help here, because the film gives none. The American Cancer Society projects 13,910 new soft tissue cancers in the United States in 2026, and 5,400 deaths. SEER publishes those projections next to its own measurements. NCI itself measures the rate at 3.5 new cases per 100,000 people per year. In 2023 an estimated 181,366 people in the country were living with a soft tissue cancer.

Stage at diagnosis matters. SEER reports that 56.8% of these cancers are found while still localized, meaning they have not spread. The 5-year relative survival for localized disease is 83.3%. Those two come from people diagnosed from 2016 through 2022.

NCI's sarcoma page states that it does not have PDQ evidence-based information about screening for soft tissue sarcoma. No test is recommended for people without symptoms.

That is different from cancers where a screening program exists. For cancers where screening is supported, see cancer screening. NCI says to check with your doctor about a lump or swelling, or pain that does not go away.

Sarcoma is graded, not just staged. Grade describes how abnormal the cancer cells look. The UICC staging system uses the three-level FNCLCC grade. It is scored from:

• how closely the tumor looks like normal tissue
• how many cells are dividing
• how much dead tissue it contains

NCI's PDQ summary is blunt about the limits of stage here. It notes that staging is mainly used as a research tool and does not routinely drive decisions. What does matter are the subtype, the grade, where the tumor sits, and whether the disease is local, locally advanced, or metastatic (spread to distant parts of the body).

PDQ also lists what shifts the outlook:

• the subtype
• the size and grade of the tumor
• its location
• whether surgery removed all of it
• the person's age and general health
• whether the cancer has come back

For sarcomas of the arms and legs, the goal is to remove the tumor and keep the limb. In one randomized trial of 141 people treated with limb-sparing surgery, radiation was 45 Gy (gray, the unit for radiation dose) to a wide area, plus an 18 Gy boost to the tumor bed. At up to 12 years, there was one local recurrence among the 70 people who received radiation, against 17 among the 71 who did not.

Chemotherapy after surgery (called adjuvant treatment) is less settled. A meta-analysis (a study that pools the results of many trials) of 1,568 individual patients across 14 trials of doxorubicin-based adjuvant treatment found an absolute 10% improvement in distant relapse-free interval. A later trial-level analysis put the absolute reduction in overall mortality at 6% for any chemotherapy and 11% for doxorubicin with ifosfamide. Then EORTC-62931 randomly assigned 351 people after local therapy and found no significant difference in either overall or relapse-free survival.

For the nerve-sheath sarcoma, NCI names one regimen specifically: ifosfamide with etoposide. Both are given on days 1, 2 and 3 and repeated every 21 days, at amounts the treating team calculates.

Several moments ring true:

• Googling your own survival rate within the first hour.
• Chemotherapy as long, dull hours in a room and a chair, with other people, not a quick montage.
• The friend who is useless and essential at once.
• The way everyone else's feelings become one more thing the patient has to manage.
• The therapist who is out of her depth and helps anyway.

Adam is handed a number as though it were a coin flip. Real estimates do not arrive that way. They are group figures with a range of uncertainty, built from people whose subtype, grade, tumor size and surgery were all different from each other.

The film also skips grade entirely, which is the single number a sarcoma team would be discussing. And it treats treatment as one undifferentiated block. In real care, the sequence is where the real conversations happen: biopsy, then surgery, then radiation timing, then a genuinely uncertain chemotherapy decision.

Cancer Explained carries no advertising and sells nothing. If this made a term clearer, or nudged you toward a question you had been avoiding, you can help keep it free for the next person. Support our work.

50/50 is a good film and a poor guide to sarcoma. Two things survive the translation. A change that persists without explanation is worth a conversation, even in a young person. And a percentage handed across a desk describes a crowd, not you.

• NCI — Soft Tissue Sarcoma Treatment (PDQ®), Health Professional Version
• NCI — Soft Tissue Sarcoma Treatment (PDQ®), Patient Version
• NCI — Soft Tissue Sarcoma, Patient Version overview
• SEER Cancer Stat Facts: Soft Tissue Cancer Including Heart

This page discusses 50/50 for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email corrections@cancerexplained.org.